亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

863-P: A Multicenter, Randomized, Open-Label, Controlled Study on Evaluating the Efficacy and Safety of Switching from Daily DPP-4 Inhibitors to Cofrogliptin in Patients with Type 2 Diabetes Mellitus in China

医学 2型糖尿病 内科学 糖尿病 打开标签 随机对照试验 多中心研究 药理学 内分泌学
作者
Chen Pan,Liming Chen,HONGWEI JIANG,Yi Feng,S Wang,Jin Zhang,ZHONGJING WANG,Yu Zhou
出处
期刊:Diabetes [American Diabetes Association]
卷期号:74 (Supplement_1)
标识
DOI:10.2337/db25-863-p
摘要

Introduction and Objective: Cofrogliptin is a novel ultra-long-acting DPP-4 inhibitor (DPP-4i) which could maintain good glycemic control in type 2 diabetes (T2D) patients with 10mg dose once biweekly. This study aims to assess the efficacy and safety of switching daily DPP-4i to cofrogliptin in Chinese T2D patients, focusing on blood glucose fluctuations. Methods: T2D patients previously treated by daily DPP-4i with or without metformin for at least 12 weeks were included. Eligible patients were randomly 1:1 assigned to the daily DPP-4i group (continued their medication) or the cofrogliptin group (switched the daily DPP-4i to biweekly cofrogliptin) for the treatment of 24 weeks. 14-day CGM was conducted from week -2 to 0 and from week 22 to 24. The primary endpoint was the change in time in range (TIR, 3.9-10.0 mmol/L) from baseline to 24 weeks. Results: A total of 64 participants with mean HbA1c of 7.04% and TIR of 83.79% were enrolled. After 24-week treatment, the mean TIR (%) relative to baseline changed by an increase of 0.545 in the cofrogliptin group and a decrease of 9.614 in the daily DPP-4i group. There was a significant difference between the two groups with least-squares (LS) mean difference of 10.159 (95%CI: 3.194, 17.124, P=0.0050). The change in mean glucose (MG, mmol/L) and coefficient of variation (CV, %) from baseline also showed significant difference with LS Mean difference of -1.016 (95%CI: -1.644, -0.388, P=0.0020) and -3.370 (95%CI: -5.998, -0.741, P=0.0129) in favor of the cofrogliptin group. There were no severe hypoglycemia events in both groups and the incidence of adverse events was similar between the two groups. Conclusion: The treatment of switching to cofrogliptin from daily DPP-4i resulted in better maintenance of TIR, MG, and CV in T2D patients, irrespective of metformin co-use, and showed good tolerability and safety. Clinical trial information: NCT06703268. Disclosure C. Pan: None. L. Chen: None. H. Jiang: None. Y. Feng: None. S. Wang: None. J. Zhang: None. Z. Wang: None. Y. Zhou: None.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ellie完成签到 ,获得积分20
3秒前
JA完成签到,获得积分10
4秒前
XM4完成签到,获得积分10
8秒前
XM3完成签到,获得积分10
13秒前
失眠的保温杯完成签到,获得积分10
15秒前
李木禾完成签到 ,获得积分10
16秒前
17秒前
XM2完成签到,获得积分10
17秒前
XM1完成签到,获得积分10
22秒前
amiee发布了新的文献求助10
24秒前
BP完成签到,获得积分10
26秒前
鱼鱼完成签到 ,获得积分10
28秒前
简单柏柳完成签到,获得积分10
47秒前
腼腆的乘云完成签到,获得积分10
50秒前
Dingwang完成签到 ,获得积分20
1分钟前
李东东完成签到 ,获得积分10
1分钟前
落后的雪青完成签到,获得积分10
1分钟前
光亮的幻桃完成签到,获得积分10
1分钟前
忍冬完成签到,获得积分10
2分钟前
2分钟前
神勇凡英完成签到,获得积分10
2分钟前
风趣的莫英完成签到,获得积分10
2分钟前
2分钟前
高贵的晓啸完成签到,获得积分10
3分钟前
3分钟前
betsydouglas14完成签到,获得积分10
3分钟前
王哇噻完成签到 ,获得积分10
3分钟前
大医仁心完成签到 ,获得积分0
3分钟前
迷路曼荷完成签到,获得积分10
3分钟前
n01W97的应助被科研通管家采纳,获得20
3分钟前
3分钟前
飘逸的易梦完成签到,获得积分10
3分钟前
dnpl完成签到,获得积分10
3分钟前
4分钟前
天真的音完成签到,获得积分10
4分钟前
江流儿完成签到,获得积分10
4分钟前
xun完成签到,获得积分20
4分钟前
4分钟前
4分钟前
文静的惜霜完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185298
求助须知:如何正确求助?哪些是违规求助? 9574106
关于积分的说明 21834276
捐赠科研通 7782800
什么是DOI,文献DOI怎么找? 3434540
关于科研通互助平台的介绍 2558812
邀请新用户注册赠送积分活动 2481237